Moderna busca aprobación de su vacuna para menores de seis años

8 de Noviembre de 2024

Moderna busca aprobación de su vacuna para menores de seis años

FRANCE-HEALTH-VIRUS-MODERNA-VACCINE

This creative image taken in a studio in Paris on November 16, 2020, showing a syringe and a vaccine vial with the reproducted logo of a US biotech firm Moderna, illustrates the announcement of an experimental vaccine against Covid-19 from Moderna that would be nearly 95% effective, marking a second major step forward in the quest to end the Covid-19 pandemic. (Photo by JOEL SAGET / AFP) / �The erroneous mention[s] appearing in the metadata of this photo by JOEL SAGET has been modified in AFP systems in the following manner: [This creative image taken in a studio in Paris on November 16, 2020, showing a syringe and a vaccine vial with the reproducted logo of a US biotech firm Moderna, illustrates the announcement of an experimental vaccine against Covid-19 from Moderna that would be nearly 95% effective, marking a second major step forward in the quest to end the Covid-19 pandemic.] instead of [This illustration picture taken in a studio in Paris on November 16, 2020, shows a syringe and a vial with the logo of US biotech firm Moderna.]. Please immediately remove the erroneous mention[s] from all your online services and delete it (them) from your servers. If you have been authorized by AFP to distribute it (them) to third parties, please ensure that the same actions are carried out by them. Failure to promptly comply with these instructions will entail liability on your part for any continued or post notification usage. Therefore we thank you very much for all your attention and prompt action. We are sorry for the inconvenience this notification may cause and remain at your disposal for any further information you may require.�

/

JOEL SAGET/AFP

This creative image taken in a studio in Paris on November 16, 2020, showing a syringe and a vaccine vial with the reproducted logo of a US biotech firm Moderna, illustrates the announcement of an experimental vaccine against Covid-19 from Moderna that would be nearly 95% effective, marking a second major step forward in the quest to end the Covid-19 pandemic. (Photo by JOEL SAGET / AFP) / “The erroneous mention[s] appearing in the metadata of this photo by JOEL SAGET has been modified in AFP systems in the following manner: [This creative image taken in a studio in Paris on November 16, 2020, showing a syringe and a vaccine vial with the reproducted logo of a US biotech firm Moderna, illustrates the announcement of an experimental vaccine against Covid-19 from Moderna that would be nearly 95% effective, marking a second major step forward in the quest to end the Covid-19 pandemic.] instead of [This illustration picture taken in a studio in Paris on November 16, 2020, shows a syringe and a vial with the logo of US biotech firm Moderna.]. Please immediately remove the erroneous mention[s] from all your online services and delete it (them) from your servers. If you have been authorized by AFP to distribute it (them) to third parties, please ensure that the same actions are carried out by them. Failure to promptly comply with these instructions will entail liability on your part for any continued or post notification usage. Therefore we thank you very much for all your attention and prompt action. We are sorry for the inconvenience this notification may cause and remain at your disposal for any further information you may require.”
Foto: AFP

La farmacéutica incluyó a 6 mil 900 niños menores de 6 años, incluidos bebés de hasta 6 meses, en un estudio con dosis de 25 microgramos

Moderna solicitara a los reguladores de Estados Unidos que apruebe su vacuna de dosis reducida para inmunizar contra la Covid-19 a bebés, niños pequeños y niños en edad preescolar

La farmacéutica adelantó que, de ser aprobada, se podría comenzar la vacunación de los menores en Estados Unidos en el verano.

La compañía también busca que se autoricen inyecciones de dosis más grandes para niños mayores y adolescentes.

Moderna señaló que su vacuna permite altos niveles de desarrollo de anticuerpos que combaten el virus a partir de inyecciones que contenían una cuarta parte de la dosis administrada a los adultos.

Sin embargo, los primeros resultados del estudio encontraron su vacuna es menos eficaz contra la variante más contagiosa de Omicron que contra las cepas anteriores.

LEE TAMBIÉN: Inicia vacunación antiCovid en menores de 5 a 12 años de Coahuila

El presidente de Moderna, Stephen Hoge, dijo que “la vacuna proporciona el mismo nivel de protección contra la COVID en niños pequeños que en adultos. Creemos que son buenas noticias”.

En el caso de Estados Unidos, el único grupo poblacional que no elegible de ser inmunizado son los menores de 5 años, que son aproximadamente 18 millones de niños.

Actualmente, Pfizer el único que cuenta con una dosis para niños y niñas de primaria y un refuerzo para mayores de 12 años.

Moderna incluyó a 6 mil 900 niños menores de 6 años, incluidos bebés de hasta 6 meses, en un estudio de las dosis de 25 microgramos.

Sostuvo que esa dosis es suficiente para desarrollar niveles de anticuerpos tan fuertes como los de los adultos jóvenes que reciben inyecciones de fuerza completa. DJ

ES DE INTERÉS |

https://www.ejecentral.com.mx/piden-a-mexico-sumar-a-ninas-y-ninos-a-vacunacion-anticovid/